Lupin receives USFDA approval for Tolvaptan Tablets
Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company.
Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity.
This product will be manufactured at Lupin's Nagpur facility in India and will be launched soon.
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
Dr. Reddy's formulations facility in AP gets 7 U.S. FDA observations
The U.S. Food and Drug Administration (U.S. FDA) has issued seven observations to Dr. Reddy's Laboratories after an inspection of the generic drugmaker's formulations manufacturing facility in Srikakulam, Andhra Pradesh. 'The U.S. FDA today completed a GMP and a pre-approval inspection (PAI) at our formulations manufacturing facility FTO 11 in Srikakulam, AP. The inspection was conducted from July 10-18. We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline,' Dr. Reddy's said in a filing on Friday.
Business Standard
3 days ago
- Business Standard
Indices trade lower; pharma shares under pressure
The key equity benchmarks continued to trade with significant cuts in mid-morning trade despite positive global cues. Investors are monitoring India-US trade deal and ongoing corporate earnings. The Nifty hovered below 25,000 level Pharma shares dropped after advancing in the past trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex declined 493.72 points or 0.60% to 81,757.65. The Nifty 50 index fell 145 points or 0.58% to 24,965.45. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index shed 0.41% and the S&P BSE Small-Cap index declined 0.46%. The market breadth was weak. On the BSE, 1,399 shares rose and 2,358 shares fell. A total of 197 shares were unchanged. Buzzing Index: The Nifty pharma index declined 0.69% to 22,522.90. The index advanced 0.38% in the past trading session. Lupin (down 1.3%), Divis Laboratories (down 1.3%), Granules India (down 1.15%), Zydus Lifesciences (down 1.06%) and Aurobindo Pharma (down 0.94%), Sun Pharmaceutical Industries (down 0.86%), Ipca Laboratories (down 0.85%), J B Chemicals & Pharmaceuticals (down 0.73%), Cipla (down 0.68%) and Dr Reddys Laboratories (down 0.67%) declined. Lupin declined 1.3%. The company announced that its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), has received GMP certification from the Therapeutic Goods Administration (TGA), Australias regulatory authority for medicines and medical devices. Stocks in Spotlight: Ceat fell 1.04% after the company's net profit declined 27.06% to Rs 112.45 crore on a 10.54% increase in revenue to Rs 3,529.41 crore in Q1 FY26 over Q1 FY25. Global Markets: Asian shares were trading higher on Friday, taking cues from Wall Street's rally overnight. Investors cheered a batch of upbeat US economic reports and corporate earnings that comfortably beat expectations. In Japan, inflation showed some signs of cooling. Core inflation for June eased to 3.3%, down from Mays 29-month high of 3.7%, with rice prices showing signs of moderation. Headline inflation also slipped to 3.3%, from 3.5% the previous month. However, the "core-core" inflation gauge, closely tracked by the Bank of Japan, as it strips out both food and energy, edged up to 3.4%, hinting that underlying price pressures are still in play. Over on Wall Street, the S&P 500 and Nasdaq closed at record highs on Thursday. Strong earnings and resilient consumer spending drove the rally. The Dow Jones rose 0.52%, while the S&P 500 climbed 0.54%, and the Nasdaq jumped 0.74%. Investors also brushed off worries about new US trade tariffs set to kick in from August 1 under President Trump, focusing instead on growth and AI-fueled optimism. Taiwanese chip giant TSMC stole the spotlight with stellar earnings and a bullish outlook on AI-related demand. Its US-listed shares surged 3.4%, igniting gains across the semiconductor and tech sectors. Adding to the momentum, US retail sales rebounded strongly in June after two months of decline. Sales rose 0.6% month-on-month, reversing a 0.9% dip in May, thanks to increased auto purchases and a still-healthy consumer.
Business Standard
3 days ago
- Business Standard
Lupin's arm receives GMP certification from Australia's TGA
Lupin announced that its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), has received GMP certification from the Therapeutic Goods Administration (TGA), Australia's regulatory authority for medicines and medical devices. The certification applies to LMSs active pharmaceutical ingredient (API) manufacturing facility in Dabhasa, Gujarat. LMS provides pharmaceutical contract development and manufacturing organization (CDMO) services, focusing on the production and supply of APIs. Dr. Abdelaziz Toumi, chief executive officer, Lupin Manufacturing Solutions. We are pleased to have received the GMP certification from TGA for our Dabhasa facility. This reflects the high standard of our manufacturing practices and expertise of our team at Dabhasa, As we continue to expand our global footprint, we remain focused on quality, compliance, and the highest standards of operational integrity, setting new benchmarks in the CDMO space. Meanwhile, the company notify that the U.S. FDA inspected Lupins Pithampur Unit-3 manufacturing facility from July 07 to July 17, 2025. The inspection closed with the issuance of a Form-483 with three observations. We will address the observations and collaborate with the U.S. FDA to resolve them within the stipulated timeframe. We are committed to be compliant with CGMP quality standards across all our facilities. In other regulatory updates, Lupin disclosed that the U.S. Food and Drug Administration (FDA) conducted inspections at its Pithampur manufacturing facilities. The inspection of Pithampur Unit-3 took place from 7 July to 17 July 2025, resulting in a Form-483 with three observations. Similarly, the Pithampur Unit-2 facility was inspected from 8 July to 17 July 2025, with four observations noted in the Form-483. The company confirmed that it is actively addressing all observations and will work closely with the U.S. FDA to resolve them within the stipulated timeframe. Lupin reaffirmed its commitment to maintaining compliance with current Good Manufacturing Practice (CGMP) quality standards across all its manufacturing units. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.94% to Rs 1,937 on the BSE.
